Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer

Han, Liang; Huang, Rongqin; Li, Jianfeng; Liu, Shuhuan; Huang, Shixian; Jiang, Chen

doi:10.1016/j.biomaterials.2010.09.070

Cited by 183 publications

(128 citation statements)

References 28 publications

Supporting

Mentioning

124

Contrasting

Order By: Relevance

“…In vivo, the following intravenous administration of this dendriplex led to a synergy between the two therapeutic entities carried by the same dendrimer, resulting in the inhibition of 77% tumor growth on mice bearing subcutaneous Bel-7402 human hepatoma. This impressive therapeutic effect was much higher than that observed with the drug only or the non-targeted dendrimer [12].…”

Section: Recent Use Of Transferrin-bearing Dendrimers For Cancer Therapymentioning

confidence: 66%

See 1 more Smart Citation

Transferrin-Bearing Dendrimers for Cancer Therapy: an Update

Somani

Dufès

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Section: Recent Use Of Transferrin-bearing Dendrimers For Cancer Therapymentioning

confidence: 66%

“…In a study by Han and colleagues, a PEGylated generation 5-poly (amido amine) (PAMAM) dendrimer was conjugated to the peptide HAIYPRH (T7), which is transferrin receptor-specific [12].…”

Section: Recent Use Of Transferrin-bearing Dendrimers For Cancer Therapymentioning

confidence: 99%

Transferrin-Bearing Dendrimers for Cancer Therapy: an Update

Somani

Dufès

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

“…Tf receptor-mediated uptake of DNA and drugs has been extensively studied on numerous cancer cell lines [17][18][19][20][21][22], but rarely on prostate cancers. Although the difference between treatments was less pronounced in our study, our results were in accordance with previous data obtained by Sahoo and colleagues [23], who demonstrated that the uptake of Tf-conjugated, paclitaxel-loaded nanoparticles was about 3-fold higher than that of unconjugated nanoparticles in PC-3 cells.…”

Section: Discussionmentioning

confidence: 99%

“…In order to remediate to this problem, we hypothesized that a generation 3-diaminobutyric polypropylenimine In this study, we successfully demonstrated that the conjugation of Tf on the dendriplexes improved DNA uptake by the three prostate cancer cell lines studied, compared to control dendriplexes and naked DNA treatment. Tf receptor-mediated uptake of DNA and drugs has been extensively studied on numerous cancer cell lines [17][18][19][20][21][22], but rarely on prostate cancers. Although the difference between treatments was less pronounced in our study, our results were in accordance with In the DU145 xenograft model, the therapeutic effect of DAB-Tf dendriplex encoding TNF± was more pronounced than that obtained with TRAIL and IL-12, contrarily to what was observed in our anti-proliferative assay in vitro.…”

mentioning

confidence: 99%

Therapeutic Efficacy of Intravenously Administered Transferrin-Conjugated Dendriplexes on Prostate Carcinomas

et al. 2014

View full text Add to dashboard Cite

This version is available at https://strathprints.strath.ac.uk/42676/ Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.ukThe Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the management and persistent access to Strathclyde's intellectual output. would be an attractive anti-cancer treatment strategy, however the lack of suitable carrier systems able to selectively deliver therapeutic genes to tumors has so far limited this investigation. Given that transferrin receptors are overexpressed on prostate cancer cells, the purpose of this study is to determine whether transferrinbearing dendriplex encoding TNF±, TRAIL and IL-12 would suppress the growth of prostate cancer cell lines in vitro and in vivo. TITLE Materials & Methods:Transferrin-bearing dendriplexes encoding TNF±, TRAIL and IL-12 were intravenously administered to mice bearing subcutaneous PC-3 and DU145 tumors. Results:The administration of the DAB-Tf dendriplex encoding TNF± resulted in tumor suppression for 60% of PC-3 and 50% of DU145 prostate tumors. Conclusions:These dendriplexes hold great potential as a novel approach for prostate cancer therapy. KEYWORDS 4 MATERIALS & METHODS Cell lines and reagents Preparation of transferrin-bearing polypropylenimine dendrimerGeneration 3-diaminobutyric polypropylenimine dendrimer (DAB, 24 mg) was conjugated to transferrin (Tf, 6 mg) by cross-linking with dimethylsuberimidate (DMSI, 12 mg) in triethanolamine HCl buffer (pH 7.4, 2 mL), as previously described 8 Statistical AnalysisResults were expressed as means ± standard error of the mean (S.E.M). Statistical significance was assessed by one-way analysis of variance (ANOVA) and Bonferroni multiple comparison post-test (GraphPad Prism software). P values lower than 0.05 were considered statistically different. 9 RESULTS Cellular uptake of DNAConfocal microscopy experiments confirmed that Cy3-labelled DNA was taken up by PC-3, DU145 and LNCaP cells (Figure 1). The fluorescently-labeled DNA was found to be disseminated in the cytoplasm following treatment with DAB-Tf and DAB dendriplexes in the three teste...

show abstract

“…[78] Jiang and co-workers conjugated PEG to PAMAM dendrimer and used the obtained copolymer (PEG-PAMAM) as a carrier to deliver DOX and DNA. [79] A tumor-targeting peptide that specifically targeted transferrin receptors-expressing cancer cells was linked to the end of PEG to enhance in vivo tumor accumulation. The tumor-targeting and DOX/DNA-loaded PEG-PAMAM nanoparticles improved endocytosis as well as gene expression efficiency in human liver tumor cells.…”

Section: Poly(amido Amine) (Pamam) Dendrimer-based Nanoparticlesmentioning

confidence: 99%

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

Thambi

Lee

2017

Adv Healthcare Materials

107

View full text Add to dashboard Cite

Drug and gene delivery systems based on nanoparticles, microparticles and hydrogels have been widely studied for cancer treatment in the past decade. To achieve an efficient and safe delivery, selection of drug and gene delivery carrier is critical. Biocompatible polymeric nanoparticles are considerably promising carrier candidates in delivery of drugs and genes because of their unique chemical and physical properties. However, delivery of a drug or gene sometimes cannot achieve a satisfactory treatment effect. Therefore, co‐delivery of dual drugs or co‐delivery of a drug and a gene in a polymeric nanoparticle has attracted attention. Such co‐delivery systems can overcome multi‐drug resistance of chemical drugs and achieve a synergistic therapeutic effect. In this progress report, we summarize recent progress in the preparation and application of polymeric drug and gene co‐delivery nanosystems. The remaining challenges and future trends in this field are also included.

show abstract

Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer

Cited by 183 publications

References 28 publications

Transferrin-Bearing Dendrimers for Cancer Therapy: an Update

Transferrin-Bearing Dendrimers for Cancer Therapy: an Update

Therapeutic Efficacy of Intravenously Administered Transferrin-Conjugated Dendriplexes on Prostate Carcinomas

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

Contact Info

Product

Resources

About